-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Calithera to Present at the H.C. Wainwright Global Investment Conference
Calithera to Present at the H.C. Wainwright Global Investment Conference
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and chief executive officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 both virtually and in Miami, FL.
The presentation will be available for on-demand viewing starting Tuesday, May 24 at 7:00 a.m. Eastern Time, and can be accessed through the Investors section of the Company's website at . The replay of the webcast will be available on the Company's website for 30 days.
About Calithera
Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers for which there are currently limited treatment options.
Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit .
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera's product candidates, the overall advancement of Calithera's product candidates in preclinical development and clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera's plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or be successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
CONTACTS:
Stephanie Wong
Chief Financial Officer
650.870.1063
ir@Calithera.com
INVESTORS:
Burns McClellan
Lee Roth
212.213.0006
lroth@burnsmc.com
SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company's founder, president and chief executive officer, will present at the H.C. Wainwright Global Investment Conference, being held May 23-25 both virtually and in Miami, FL.
加利福尼亚州南旧金山,2022年5月17日(环球网)--临床阶段、精确肿瘤学生物制药公司卡里瑟拉生物科学公司(纳斯达克代码:CALA)今天宣布,公司创始人、总裁兼首席执行官苏珊·莫利诺博士将出席5月23-25日在佛罗里达州迈阿密举行的H.C.温赖特全球投资大会。
The presentation will be available for on-demand viewing starting Tuesday, May 24 at 7:00 a.m. Eastern Time, and can be accessed through the Investors section of the Company's website at . The replay of the webcast will be available on the Company's website for 30 days.
演示文稿将于5月24日(星期二)上午7:00开始提供点播观看。东部时间,可通过公司网站的投资者部分访问。网络直播的重播将在公司网站上播放30天。
About Calithera
关于卡里瑟拉
Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations. Driven by a commitment to rigorous science and a passion for improving the lives of people impacted by cancer and other life-threatening diseases, Calithera is advancing a robust pipeline of investigational, small molecule oncology compounds with a biomarker-driven approach that targets genetic vulnerabilities in cancer cells to deliver new therapies for patients suffering from aggressive hematologic and solid tumor cancers for which there are currently limited treatment options.
卡利瑟拉生物科学公司是一家临床阶段、精确的肿瘤学生物制药公司,开发有针对性的治疗方法,以重新定义生物标记物特定患者群体的治疗。在对严谨科学的承诺和对改善受癌症和其他危及生命的疾病影响的人们的生活的热情的推动下,Calithera正在推进一系列强大的研究、小分子肿瘤化合物的管道,采用生物标记物驱动的方法,针对癌细胞中的遗传脆弱性,为患有侵袭性血液病和实体瘤癌症的患者提供新的治疗方法,目前这些患者的治疗选择有限。
Calithera is headquartered in South San Francisco, California. For more information about Calithera, please visit .
卡利瑟拉公司总部设在加利福尼亚州旧金山南部。欲了解更多关于卡利瑟拉的信息,请访问。
Forward Looking Statements
前瞻性陈述
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," "poised" and similar expressions (as well as other words or expressions referencing future events, conditions, or circumstances) are intended to identify forward-looking statements. These statements include those related to the safety, tolerability and efficacy of Calithera's product candidates, the overall advancement of Calithera's product candidates in preclinical development and clinical trials, the unmet need in the treatment of patients with advanced disease, and Calithera's plans to continue development of its product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all. In addition, clinical trials may not confirm any safety, potency or other product characteristics described or assumed in this press release. Such product candidates may not be beneficial to patients or be successfully commercialized. The failure to meet expectations with respect to any of the foregoing matters may have a negative effect on Calithera's stock price. Additional information concerning these and other risk factors affecting Calithera's business can be found in Calithera's periodic filings with the Securities and Exchange Commission at www.sec.gov. These forward-looking statements are not guarantees of future performance and speak only as of the date hereof, and, except as required by law, Calithera disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.
本新闻稿中包含的有关非历史事实的陈述属于“1995年私人证券诉讼改革法案”所指的“前瞻性陈述”。“可能”、“将”、“预期”、“预期”、“估计”、“打算”、“稳妥”等词语和类似的表述(以及涉及未来事件、条件或情况的其他词语或表述)旨在识别前瞻性表述。这些陈述包括与卡列瑟拉候选产品的安全性、耐受性和有效性、卡列瑟拉候选产品在临床前开发和临床试验中的整体进步、晚期疾病患者的治疗方面未得到满足的需求以及卡列瑟拉继续开发其候选产品的计划有关的声明。由于此类陈述受风险和不确定因素的影响,实际结果可能与此类前瞻性陈述所表达或暗示的结果大不相同。Calithera开发的潜在候选产品可能不会在预期的时间内或根本不能通过临床开发或获得所需的监管批准。此外,临床试验可能不能证实本新闻稿中描述或假定的任何安全性、有效性或其他产品特性。这样的候选产品可能不会对患者有益,也可能不会成功商业化。如果未能达到上述任何事项的预期,可能会对卡利瑟拉的股票价格产生负面影响。有关影响卡利瑟拉公司业务的这些和其他风险因素的更多信息,可在卡利瑟拉公司提交给证券交易委员会的定期文件中找到,网址为www.sec.gov。这些前瞻性陈述不是对未来业绩的保证,仅在本文发布之日起发表,并且,除法律另有要求外, 卡利瑟拉公司没有义务更新这些前瞻性陈述,以反映未来的事件或情况。
CONTACTS:
Stephanie Wong
Chief Financial Officer
650.870.1063
ir@Calithera.com
触点:
斯蒂芬妮·王
首席财务官
650.870.1063
邮箱:ir@Calithera.com
INVESTORS:
Burns McClellan
Lee Roth
212.213.0006
lroth@burnsmc.com
投资者:
伯恩斯·麦克莱伦
李·罗斯
212.213.0006
邮箱:lroth@burnsmc.com
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧